Status:
UNKNOWN
Non-invasive Evaluation of Cerebrovascular Reactivity in Spontaneous Intracerebral Hemorrhage
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Intracerebral Hemorrhage
Eligibility:
All Genders
20-90 years
Phase:
PHASE1
Brief Summary
Spontaneous intracerebral hemorrhage (ICH) remains a significant cause of morbidity and mortality around the globe. The most common etiology of nontraumatic spontaneous ICH is hypertensive arteriopath...
Eligibility Criteria
Inclusion
- age between 20-90 years-old
- patient with spontaneous intracerebral hemorrhage or healthy control
- consciousness clear
- willing to receive brain MRI
Exclusion
- renal failure or Creatinine \> 2mg/dl
- coagulopathy or hepatic insufficiency
- unstable vital sign under inotropic agents
- allergy to Dipyridamole
- pregnancy
- asthma history
- metal implant or cardiac pacemaker
Key Trial Info
Start Date :
January 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03815513
Start Date
January 21 2019
End Date
December 31 2020
Last Update
January 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 10048